A detailed history of Advisor Group Holdings, Inc. transactions in Biovie Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 3,963 shares of BIVI stock, worth $10,977. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,963
Previous 5,763 31.23%
Holding current value
$10,977
Previous $3,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.4 - $0.56 $720 - $1,008
-1,800 Reduced 31.23%
3,963 $1,000
Q1 2024

May 10, 2024

SELL
$0.53 - $1.89 $702 - $2,504
-1,325 Reduced 18.69%
5,763 $3,000
Q4 2023

Feb 12, 2024

SELL
$1.22 - $5.24 $2,116 - $9,091
-1,735 Reduced 19.66%
7,088 $8,000
Q3 2023

Nov 13, 2023

SELL
$2.75 - $5.17 $566 - $1,065
-206 Reduced 2.28%
8,823 $30,000
Q2 2023

Aug 10, 2023

BUY
$4.09 - $8.29 $4,355 - $8,828
1,065 Added 13.37%
9,029 $38,000
Q1 2023

May 12, 2023

SELL
$4.89 - $10.53 $8,503 - $18,311
-1,739 Reduced 17.92%
7,964 $64,000
Q4 2022

Feb 10, 2023

BUY
$3.86 - $42.0 $25,726 - $279,930
6,665 Added 219.39%
9,703 $75,000
Q3 2022

Nov 14, 2022

BUY
$1.38 - $25.6 $3,725 - $69,120
2,700 Added 798.82%
3,038 $8,000
Q2 2022

Aug 10, 2022

SELL
$1.44 - $5.04 $953 - $3,336
-662 Reduced 66.2%
338 $0
Q1 2022

May 04, 2022

BUY
$2.74 - $5.65 $822 - $1,695
300 Added 42.86%
1,000 $5,000
Q2 2021

Aug 02, 2021

BUY
$10.57 - $21.61 $5,285 - $10,805
500 Added 250.0%
700 $11,000
Q1 2021

May 13, 2021

SELL
$14.35 - $44.81 $11,480 - $35,848
-800 Reduced 80.0%
200 $4,000
Q4 2020

Feb 10, 2021

SELL
$7.85 - $17.32 $39,250 - $86,600
-5,000 Reduced 83.33%
1,000 $17,000
Q3 2020

Nov 12, 2020

BUY
$9.0 - $265.0 $54,000 - $1.59 Million
6,000 New
6,000 $58,000

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $83.6M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.